Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KRAS G12D siRNA for Metastatic Pancreas Cancer Patients Harboring KRAS G12D Mutation

Summary

The purpose of this phase I study is to evaluate the safety and feasibility of KRAS G12D siRNA (iExosomes) in patients with metastatic pancreatic cancer with KRAS G12D mutation.

General Information

NCT#: NCT03608631
Study ID: 2018-0126
Trial Phase: Phase I

Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: iExosomes

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search